Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma

Authors

Nancy L. Bartlett, Washington University School of Medicine in St. Louis
Armin Ghobadi, Washington University School of Medicine in St. Louis
et al

Journal

Molecular Therapy

Publication Date

2017

Volume

25

Issue

1

Inclusive Pages

285-295

Document Type

Open Access Publication

DOI

10.1016/j.ymthe.2016.10.020

Rights and Permissions

Locke FL, et al (2017) Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 25(1):285-295. https://doi.org/10.1016/j.ymthe.2016.10.020 Copyright 2017 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Bartlett, Nancy L.; Ghobadi, Armin; and et al, "Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma." Molecular Therapy. 25, 1. 285-295. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5899